Molecular science and technology firm ConcertAI and Caris Life Sciences have formed a partnership to develop translational and clinical development research platforms that will support drug development and therapeutics research.
The partnership will integrate Caris' genomic, transcriptomic, and proteomic database with ConcertAI's oncology, hematology, and urological cancer clinical data, the latter of which includes information on the treatment and outcomes of roughly 7 million patients, the company said.
